Neurostimulation: Technologies and Global Markets

  • March 2014
  • -
  • BCC Research
  • -
  • 137 pages

REPORT HIGHLIGHTS

The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.

This report provides:


An overview of the global market for neurostimulation devices, many of which currently are in clinical trials or undergoing development to treat a range of disorders, including epilepsy, obesity, Parkinson’s disease, depression, sexual dysfunction, urinary tract disorders, and drug addiction
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
A focus on individual disorders and variety of neurostimulation options, which include deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation, and closed-loop/responsive stimulation
Examination of positive market impacts, which include increasing acceptance of neurostimulation devices for multiple applications, an aging population market, and technological advancements; as well as negative impacts, which include current device recalls, risks of neurostimulation devices, and investment and funding for new technological advancements
Evaluations of new product launches, current promising clinical trials, and the patent/technological pipeline
Comprehensive company profiles of major players.

INTRODUCTION

Neurostimulation incorporates technological advancements from a variety of fields including science, medicine and bioengineering. The main goal through these technologies is to develop implantable electrical devices to improve the quality of human life and day-to-day human functioning. This involves the process of electrically inhibiting or activating the functioning of the peripheral, central or autonomic nervous systems. The earliest implantable neurostimulation devices were spinal cord stimulators and stimulators to treat cardiovascular disease. In the 1970s, deep brain stimulator devices were introduced. It was around this time that the U.S. Food and Drug Administration (FDA) required implantable devices to be regulated and compliable with patient safety measures. From the 1980s to today, neurostimulators have been mainly used to treat movement disorders.

The neurostimulation device industry has seen rapid growth in the past decade. These technological advancements have not only led to improvements in existing neurostimulation devices, but they have also aided the development of the next generation of devices.Neurostimulation devices are increasingly used for pain management. Each year it is estimated that over 100 million people globally suffer from chronic pain. Currently drug therapies are the primary treatment option; however, in the long run these therapies have proved to be ineffective. As a result, in the current neurostimulation industry devices are of increasing interest for treating chronic pain. Recently a large number of neurostimulation devices have begun clinical trials or are undergoing development to treat a range of disorders including: epilepsy, obesity, Parkinson’s disease, depression, sexual dysfunction, cardiovascular disorders, movement disorders, gastrointestinal disorders, urinary tract disorders, sensory disorders and drug addiction. This opens up a wider market of applications for neurostimulation devices.

This also points to the fact that a wide variety of clinical specialists, apart from neurosurgeons and neurologists, would be interested in applying the therapies enabled by neurostimulation.Currently, the market is underdeveloped despite technological advances due to low medical acceptance and equally low consumer awareness. Patients still fear the prospect of having a foreign object implanted into their bodies. This is anticipated to change with the commercialization of technologically advanced neurostimulators, physician training, increased venture capital and government funding and considerably due to the expansion of health insurance to the underinsured and uninsured. It should be noted that even with the expansion of health insurance, often health insurance providers do not offer full reimbursement for neurostimulation devices.

This is due to some providers being ill-informed and not being fully clear on the concept of neurostimulation as a viable treatment option. It becomes a priority for leading medical device manufacturers and physicians to inform insurance providers about the benefits and success stories of neurostimulation devices. This will lead to the successful implementation of neurostimulation devices on the market from manufacturing to implantation and through patient therapy.

STUDY GOALS AND OBJECTIVES

This report, Neurostimulation, from BCC Research includes forecasted trends and sales through 2018. Current market leaders, new technologies and factors influencing low and high demand are discussed. Neurostimulation ranges from noninvasive to minimally invasive to fully invasive. Depending upon the application, various neurostimulation devices are currently on the market.

This report is particularly focused on individual disorders and discusses a variety of neurostimulation options for each disorder—including deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation and closed-loop/responsive stimulation. Finally, the report includes information about market share, new product launches, promising technologies and current clinical trials.

REASONS FOR DOING THE STUDY

As of 2011, the size of the neurostimulation market was estimated at 4.2 billion. This market serves a patient population with both sensory and motor neural deficits. Compared to other medical device markets, the neurostimulation market can still be considered as an emerging market. At this point in time, the exiting neurostimulation technologies of spinal cord stimulation, cochlear implants and vagal nerve stimulation are widely successful. The success of these technologies with current advances in imaging technologies can provide an increase in the number of clinical applications for neurostimulation devices. These applications will also increase with the establishment of specialized medical training and a patient population eligible to benefit from the neurostimulation devices.In the past few years, these advances have led to the development of a large number of small start-up firms working on exciting new technologies. This has created a competitive market place. This report will provide the reader with an overview of neurostimulation devices available for treating individual disorders along with an overview of company profiles.

SCOPE OF REPORT

This report is a business tool that primarily will be helpful in examining trends in the market for neurostimulation devices. It begins with an overview of neurostimulation devices, key players, entry-level players, market trend analysis and factors influencing future incidence. It will also include market analysis by clinical disorder, including annual incidence, trend analysis and factors influencing future predicted surgical volume. Finally, the report will cover market share and information on key neurostimulation device manufacturers.

INTENDED AUDIENCE

This report is intended for anyone interested in better understanding the role of the rapidly growing neurostimulation technologies of the broader neuromodulation markets.Executives, consultants, trade associations, clinicians and marketing professionals in the medical device industry, health insurance industry and experts in the neuroscience and neurosurgery fields would benefit from this report. Additionally, stock analysts, venture capitalists funders and investors focused on the neuromodulation markets or those who are interested in expanding markets for neurostimulation devices would also benefit. Manufacturers and distributors of the neurostimulation technologies discussed in this report are also an intended audience.

Table Of Contents

Chapter- 1: INTRODUCTION 4

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 3

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018
Figure 0 A : DISTRIBUTION OF NEUROSTIMULATION DEVICES BY TYPE OF DISORDER CATEGORY 2012-2018
Figure 0 B : GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY 2012-2018

Chapter- 3: OVERVIEW OF NEUROSTIMULATION DEVICES

MARKET TRENDS (TECHNOLOGIES) AND MARKET SHARE (KEY PLAYERS AND ENTRY LEVEL)
POSITIVE MARKET IMPACT
NEGATIVE MARKET IMPACT

Chapter- 4: MARKET FOR NEUROSTIMULATION DEVICES

NEUROSTIMULATION FOR PAIN MANAGEMENT
NEUROSTIMULATION FOR MOVEMENT DISORDERS
NEUROSTIMULATION FOR NEUROPSYCHIATRIC DISORDERS
NEUROSTIMULATION FOR STROKE AND TRAUMATIC BRAIN INJURY
NEUROSTIMULATION FOR CARDIOVASCULAR DISORDERS
NEUROSTIMULATION FOR GASTROINTESTINAL DISORDERS
NEUROSTIMULATION FOR URINARY AND RECTAL DISORDERS
NEUROSTIMULATION FOR SENSORY DISORDERS
ADAPTIVE NEUROSTIMULATION THERAPY

Chapter- 5: COMPANY PROFILES

ADVANCED BIONICS, LLC
ALEVA NEUROTHERAPEUTICS SA
ATROTECH OY
AUTONOMIC TECHNOLOGIES INC.
AVERY BIOMEDICAL DEVICES, INC.
BIONESS INC.
BIOTRONIK SE and CO.KG
BOSTON SCIENTIFIC CORPORATION
CERBOMED GMBH
COCHLEAR AMERICAS
CVRX INC.
CYBERONICS, INC.
ENTEROMEDICS INC.
MED-EL MEDICAL ELECTRONICS
MEDTRONIC, INC.
NEUROMETRIX INC.
NEURONETICS, INC.
NEUROPACE INC.
NEUROSIGMA
NEVRO CORPORATION
SECOND SIGHT MEDICAL PRODUCTS, INC.
SPINAL MODULATION INC.
SPR THERAPEUTICS LLC
ST. JUDE MEDICAL
UROPLASTY, INC.
ZYNEX MEDICAL, INC.


List of Tables

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018
Table 1 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS
Table 2 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS
Table 3 : HEARING LOSS DEVICE GLOBAL MARKET DISTRIBUTION
Table 4 : MANUFACTURERS OF HEARING LOSS DEVICES MARKET SHARE
Table 5 : MANUFACTURERS OF OVERACTIVE BLADDER DEVICES MARKET SHARE IN NORTH AMERICA
Table 6 : MARKET SHARE OF MANUFACTURERS OF EPILEPSY DEVICES
Table 7 : MARKET SHARE OF MANUFACTURERS OF FOOT DROP DEVICES
Table 8 : MARKET SHARE OF MANUFACTURERS OF DIABETES/OBESITY DEVICES, 2012
Table 9 : RETINAL DEGENERATION MANUFACTURERS’ MARKET SHARE
Table 10 : PREMARKET APPROVALS (PMA) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
Table 11 : PREMARKET NOTIFICATION (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
Table 12 : CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
Table 13 : CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 14 : PREMARKET APPROVALS (PMA) FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
Table 15 : CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
Table 16 : PREMARKET APPROVALS (PMA) FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
Table 17 : CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
Table 18 : AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 19 : PREMARKET APPROVALS (PMA) FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 20 : CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 21 : PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 22 : PREMARKET APPROVALS (PMA) FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES
Table 23 : CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES
Table 24 : NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 25 : PREMARKET APPROVALS (PMA) FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES
Table 26 : CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
Table 27 : NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 28 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS
Table 29 : DISTRIBUTION OF RANKINGS FOR EPILEPSY BY GLOBAL REGIONS.
Table 30 : GLOBAL PREVALENCE OF EPILEPSY
Table 31 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN MALES
Table 32 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES
Table 33 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY
Table 34 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY
Table 35 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY
Table 36 : PREMARKET APPROVALS (PMA) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
Table 37 : PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
Table 38 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES.
Table 39 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES
Table 40 : NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 41 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL MALE POPULATION OF 2004
Table 42 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL FEMALE POPULATION OF 2004
Table 43 : DISTRIBUTION OF RANKINGS FOR SCHIZOPHRENIA BY REGION, 2010
Table 44 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA 2010
Table 45 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010
Table 46 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010
Table 47 : CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES
Table 48 : NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 49 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006
Table 50 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER. AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006
Table 51 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER, AS A PERCENTAGE OF TOTAL DALYS
Table 52 : DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006
Table 53 : DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP
Table 54 : CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
Table 55 : CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
Table 56 : NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 57 : GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006
Table 58 : RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010
Table 59 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, 2010
Table 60 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER’S DISEASE, 2010
Table 61 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER’S DISEASE, 2010
Table 62 : CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 63 : NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 64 : CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
Table 65 : NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 66 : DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010
Table 67 : GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004
Table 68 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006
Table 69 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES
Table 70 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS, 2006
Table 71 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010
Table 72 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010
Table 73 : CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
Table 74 : NEUROSTIMULATION AND BI-POLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 75 : DISTRIBUTION OF RANKINGS FOR DEPRESSION BY GLOBAL REGIONS, 2010
Table 76 : GLOBAL PREVALENCE OF DEPRESSION, 2004
Table 77 : GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010
Table 78 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010
Table 79 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010
Table 80 : PRE-MARKET APPROVALS (PMA) FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
Table 81 : CLINICAL TRIALS FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
Table 82 : NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 83 : RANK OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010
Table 84 : GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004
Table 85 : CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 86 : NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 87 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., FROM 1997 TO 2007
Table 88 : CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES
Table 89 : NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 90 : CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 91 : NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 92 : PRE-MARKET APPROVALS (PMA) FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 93 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES
Table 94 : NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 95 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES IN THE MALE POPULATION OF 2004
Table 96 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES, IN THE FEMALE POPULATION OF 2004
Table 97 : PRE-MARKET APPROVALS (PMA) FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES
Table 98 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY ASSOCIATED NEUROSTIMULATION DEVICES
Table 99 : NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 100 : OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008
Table 101 : OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008
Table 102 : DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010
Table 103 : DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009 TO 2010
Table 104 : PERCENTAGE OF OBESITY AMONG MALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008
Table 105 : PERCENTAGE OF OBESITY AMONG FEMALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008
Table 106 : DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010
Table 107 : DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010
Table 108 : DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010
Table 109 : CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES
Table 110 : NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 111 : PRE-MARKET APPROVALS (PMA) FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
Table 112 : CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES
Table 113 : NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 114 : PREMARKET APPROVALS (PMA) FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES
Table 115 : CLINICAL TRIALS FOR FECAL INCONTINENCE ASSOCIATED NEUROSTIMULATION DEVICES
Table 116 : NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 117 : DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010
Table 118 : GLOBAL PREVALENCE OF MODERATE OR GREATER HEARING LOSS DISEASE, 2004
Table 119 : GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004
Table 120 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY, INCLUDING HEARING, LOSS IN MALES, 2004
Table 121 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY INCLUDING HEARING LOSS, IN FEMALES
Table 122 : PREMARKET APPROVALS (PMA) FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
Table 123 : CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
Table 124 : NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 125 : CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES
Table 126 : NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
Table 127 : CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY

List of Figures

Figure 1 : MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER
Figure 2 : MARKET SHARE OF HEARING LOSS NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER
Figure 3 : SALES DISTRIBUTION OF DIABETES/OBESITY NEUROSTIMULATION DEVICES BY MANUFACTURER, 2012
Figure 4 : DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK, BY CONDITION
Figure 5 : DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK, BY BODY PARTS INCLUDING BACK
Figure 6 : DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP
Figure 7 : DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN, BY AGE GROUP
Figure 8 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS
Figure 9 : DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP
Figure 10 : GLOBAL PREVALENCE OF PARKINSON'S DISEASE
Figure 11 : NUMBER OF DEATHS GLOBALLY DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE
Figure 12 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE
Figure 13 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE
Figure 14 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS
Figure 15 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING PARKINSON'S DISEASE AS A PERCENTAGE OF TOTAL DALYS IN MALES
Figure 16 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES
Figure 17 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS
Figure 18 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS
Figure 19 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006
Figure 20 : GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004
Figure 21 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006
Figure 22 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006
Figure 23 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS, 2006
Figure 24 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006
Figure 25 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER’S, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006
Figure 26 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER’S DISEASE, AS A PERCENTAGE OF TOTAL DALYS, 2006
Figure 27 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006
Figure 28 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006
Figure 29 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006
Figure 30 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION AS A PERCENTAGE OF TOTAL DALYS, 2006
Figure 31 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007
Figure 32 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007
Figure 33 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007
Figure 34 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007
Figure 35 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007
Figure 36 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008
Figure 37 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005-2008
Figure 38 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE, IN THE MALE POPULATION OF 2004
Figure 39 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE IN THE FEMALE POPULATION OF 2004

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Drugs for Treating Systemic Lupus Erythematosus: Global Markets

Drugs for Treating Systemic Lupus Erythematosus: Global Markets

  • $ 6 650
  • Industry report
  • March 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.